These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 22480280)
1. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained. Sclar DA; Evans MA; Robison LM; Skaer TL Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280 [TBL] [Abstract][Full Text] [Related]
2. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG; Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Wencker M; Fuhrmann B; Banik N; Konietzko N; Chest; 2001 Mar; 119(3):737-44. PubMed ID: 11243951 [TBL] [Abstract][Full Text] [Related]
4. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Tonelli AR; Rouhani F; Li N; Schreck P; Brantly ML Int J Chron Obstruct Pulmon Dis; 2009; 4():443-52. PubMed ID: 20054436 [TBL] [Abstract][Full Text] [Related]
5. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency. Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857 [TBL] [Abstract][Full Text] [Related]
6. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome? Abboud RT; Ford GT; Chapman KR Treat Respir Med; 2005; 4(1):1-8. PubMed ID: 15725045 [TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Wencker M; Banik N; Buhl R; Seidel R; Konietzko N Eur Respir J; 1998 Feb; 11(2):428-33. PubMed ID: 9551749 [TBL] [Abstract][Full Text] [Related]
8. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950 [TBL] [Abstract][Full Text] [Related]
16. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839 [TBL] [Abstract][Full Text] [Related]
17. A longitudinal study of alpha1-antitrypsin phenotypes and decline in FEV1 in a community population. Silva GE; Sherrill DL; Guerra S; Barbee RA Chest; 2003 May; 123(5):1435-40. PubMed ID: 12740258 [TBL] [Abstract][Full Text] [Related]